Department of Biological Sciences, University of Hull, Hull, HU6 7RX, UK.
Thromb Res. 2013 Feb;131(2):109-15. doi: 10.1016/j.thromres.2012.11.013. Epub 2012 Dec 11.
Cancer is frequently complicated by venous thromboembolic events (VTE), which pose a significant health burden due to the associated high morbidity and mortality rates, yet the exact details of the pathophysiological mechanisms underlying their development are yet to be fully elucidated. Tissue factor (TF), the primary initiator of coagulation, is often overexpressed in malignancy and as such is a prime candidate in predicting the hypercoagulable state. Further exploration of this potential role has identified increases in the number of TF-expressing microparticles (MP) in the circulation of cancer patients, in particular in those known to have high incidences of thromboembolic complications. The risk of VTE in cancer is found to be further elevated by chemotherapy. Chemotherapy may, in eliciting cancer cell apoptosis, result in an increase in release of circulating procoagulant MP. We discuss a potential role of elevated tumour TF expression and increased circulating TF-positive MP in predicting VTE risk.
癌症常伴有静脉血栓栓塞事件 (VTE)，由于其相关的高发病率和死亡率，给健康带来了重大负担，但它们发展背后的病理生理机制的具体细节尚未完全阐明。组织因子 (TF) 是凝血的主要启动因子，在恶性肿瘤中常过度表达，因此是预测高凝状态的主要候选因子。进一步探索这种潜在作用，发现癌症患者循环中 TF 表达的微颗粒 (MP) 数量增加，特别是在已知血栓栓塞并发症发生率高的患者中。化疗会进一步增加癌症患者发生 VTE 的风险。化疗可能会导致癌细胞凋亡，从而增加循环促凝 MP 的释放。我们讨论了升高的肿瘤 TF 表达和增加的循环 TF 阳性 MP 在预测 VTE 风险中的潜在作用。
